Zevtera/Mabelio (ceftobiprole)
Community-acquired bacterial pneumonia (CABP), Staphylococcus aureus bacteremia (SAB)
MarketedCommercial / Launch (US)
Key Facts
Indication
Community-acquired bacterial pneumonia (CABP), Staphylococcus aureus bacteremia (SAB)
Phase
Marketed
Status
Commercial / Launch (US)
Company
About Basilea Pharmaceutica
Basilea Pharmaceutica is a profitable, Swiss-based biopharma company dedicated to becoming a leading global anti-infectives company. Its mission is to address the critical unmet medical need in severe infections through the commercialization of its two marketed products, Cresemba and Zevtera, and the development of a targeted pipeline of novel antibiotics and antifungals. The company's strategy leverages deep expertise in anti-infective development, regulatory navigation, and global commercialization, supported by a disciplined operational focus and strategic partnerships with entities like BARDA.
View full company profile